Similar articles for PMID: 25854340

Year	Number of Results
2001	1
2004	1
2005	1
2006	6
2007	7
2008	8
2009	7
2010	9
2011	12
2012	18
2013	20
2014	17
2015	25
2016	20
2017	20
2018	16
2019	29
2020	20
2021	15
2022	20
2023	5
2024	0

1

Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.

Okutur K, Bassulu N, Dalar L, Aydin K, Bozkurt M, Pilanci KN, Dogusoy GB, Tecimer C, Mandel NM, Demir G. Okutur K, et al. Asian Pac J Cancer Prev. 2015;16(7):2645-51. doi: 10.7314/apjcp.2015.16.7.2645. Asian Pac J Cancer Prev. 2015. PMID: 25854340 Free article.

2

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G. Razis E, et al. Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19. Breast Cancer Res Treat. 2011. PMID: 21594665 Free article.

3

PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Tekesin K, Emin Gunes M, Bayrak S, Akar E, Ozturk T, Altinay S, Tural D. Tekesin K, et al. J BUON. 2019 Sep-Oct;24(5):1920-1926. J BUON. 2019. PMID: 31786856 Free article.

4

Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Fabi A, Metro G, Di Benedetto A, Nisticò C, Vici P, Melucci E, Antoniani B, Perracchio L, Sperduti I, Milella M, Cognetti F, Mottolese M. Fabi A, et al. Oncology. 2010;78(2):141-9. doi: 10.1159/000312656. Epub 2010 Apr 13. Oncology. 2010. PMID: 20389136

5

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. Esteva FJ, et al. Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2. Am J Pathol. 2010. PMID: 20813970 Free PMC article.

6

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Tural D, Serdengecti S, Demirelli F, Öztürk T, İlvan S, Turna H, Özgüroglu M, Büyükünal E. Tural D, et al. Br J Cancer. 2014 Apr 15;110(8):1968-76. doi: 10.1038/bjc.2014.72. Epub 2014 Mar 4. Br J Cancer. 2014. PMID: 24595002 Free PMC article. Retracted.

7

p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.

Pavlakis K, Bobos M, Batistatou A, Kotoula V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G, Psyrri A, Koutras A, Pectasides D, Papakostas P, Razis E, Christodoulou C, Kalogeras KT, Fountzilas G. Pavlakis K, et al. Pathol Oncol Res. 2015 Apr;21(2):273-82. doi: 10.1007/s12253-014-9818-2. Epub 2014 Aug 8. Pathol Oncol Res. 2015. PMID: 25098276 Free article.

8

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G. Gallardo A, et al. Br J Cancer. 2012 Apr 10;106(8):1367-73. doi: 10.1038/bjc.2012.85. Epub 2012 Mar 27. Br J Cancer. 2012. PMID: 22454081 Free PMC article.

9

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L. Gori S, et al. Ann Oncol. 2009 Apr;20(4):648-54. doi: 10.1093/annonc/mdn681. Epub 2009 Feb 2. Ann Oncol. 2009. PMID: 19188134 Free article.

10

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.

Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyrri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G. Koutras A, et al. PLoS One. 2018 Dec 6;13(12):e0207707. doi: 10.1371/journal.pone.0207707. eCollection 2018. PLoS One. 2018. PMID: 30521571 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

239 results

Results by year